Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Lefebvre (South San Francisco, United States of America), B. Coulie (South San Francisco, United States of America), M. Jurek (South San Francisco, United States of America), J. Bellini (South San Francisco, United States of America), F. Cilli (South San Francisco, United States of America), S. Wong (South San Francisco, United States of America), M. Decaris (South San Francisco, United States of America), S. Turner (South San Francisco, United States of America), E. Park (South San Francisco, United States of America). INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF. 782

Member's Comments

No comment yet.

Related content which might interest you: A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019 Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002 A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection Source: Virtual Congress 2020 – Chinese programme 2020: Part I Year: 2020 Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008 The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019